Improved health status with SGLT2-inhibitor in HFrEF
This video was recorded at the AHA in Philadelphia, USA, on november 17, 2019.
Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardio Metabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.